In this Authority Magazine article, Maureen Bennett shares her journey as a mother raising her daughter Kaitlin, who has GRIN1-NDD. Maureen reflects on their family’s path from Kaitlin’s diagnosis to the daily challenges they face: medium.com/authority-maga…

In rare disease research, eligibility criteria must be precise enough to support meaningful outcomes, yet broad enough to reflect the community a therapy is intended to serve. Read our Q&A with SVP Megan Weaver on how we are tackling this delicate balance: bit.ly/43UYaXh

#DidYouKnow that FCD Type II is a rare disorder characterized by malformations of cortical development caused by abnormal brain formation in utero? Learn how we are advancing the Astroscape study for the potential treatment of FCD Type II: grintherapeutics.com

We’re proud to sponsor a session at the#2025TSCIRC, hosted by the TSC Alliance! Join us in Bethesda, MD as we connect with the community and advance research in tuberous sclerosis complex (TSC). Visit our booth to learn more.

The American Academy of Pediatrics now recommends genome/exome sequencing plus microarray as first-line tests for most children with GDD or ID, expanding support for access to advanced diagnostics that can bring families closer to answers for rare disorders like GRIN-NDD: publications.aap.org/pediatrics/art…

At #EPNS2025, we are excited to share significant progress in our efforts to address GRIN-NDD. We look forward to engaging with the pediatric #neurology community to collaborate and share knowledge as we continue our development work toward meaningful treatments.

Our team just wrapped up presentations at #IEC2025! We were proud to share updates on our clinical programs and our new study assessing caregiver perspectives on daily life with GRIN-NDD. Learn more about our presentations: prnewswire.com/news-releases/…

Proud to see our Director of Community Engagement and Communications, Hillary Savoie, PhD, share at #FiercePharmaWeek how authentic communication helps build trust with the patient advocacy community. Patient and family voices remain central to our mission in rare disease.

In a recent Q&A with Life Science Connect, our Chief Medical Officer, Michael Panzara, discusses how we’re advancing investigational radiprodil to target GRIN-related neurodevelopmental disorder (GRIN-NDD) and other serious neurodevelopmental conditions: drugdiscoveryonline.com/doc/targeting-…